Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 27, 2025Documenta Haematologica - Revista Romana de HematologieOpen Access

A Single Center’s Experience in the Diagnosis and Treatment of Myeloproliferative Neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

APAdriana Mihaela PISTOLCPConstanta Elena PopoviciNBNicoleta Berbec

Discussion

Loading...

Member takes

Overview

Observational analysis reveals common types and complications in 154 patients with MPNs, highlighting the role of risk factors.

Key Points

  • About 83% of patients diagnosed with MPNs required therapeutic intervention due to symptoms and complications.
  • Among 154 cases, 31.82% were diagnosed with polycythemia vera and essential thrombocythemia each, while 30.52% had myelofibrosis.
  • Risk factors, including cardiovascular issues, were present in over half of the patients, impacting treatment decisions and outcomes.
  • Improved diagnosis rates and emerging therapies have significantly enhanced life expectancy and quality of life for affected individuals.

Cite This Study

PISTOL et al. (2025) studied this question.

synapsesocial.com/papers/68d7be70eebfec0fc5238690https://doi.org/10.59854/dhrrh.2025.3.3.119
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinicopathological characteristics and outcome of patients with Philadelphia negative myeloproliferative neoplasms: first report from Upper Egypt2025
  2. 2Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  3. 3Thrombotic Events and Overall Survival in BCR-ABL1 Negative Myeloproliferative Neoplasms: A Single-Center Analysis2026
  4. 4Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.2025
  5. 5Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs)2025 · 7 citations